Compugen Ltd. (CGEN) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (87% profit margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, Compugen Ltd. (NASDAQ: CGEN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1.98 (-2.94% 1D, market cap $193.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, CGEN ranks #23 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEN carries a Roarable B+ (78/100 RQD), trailing P/E of 5.5x, gross margin of 87.3%, and ROIC of 85.0%. By comparison, DTIL (Precision BioSciences Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M) and ARTV (Artiva Biotherapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per CGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001119774), Compugen Ltd. generated $72.8M in revenue (+161.1% YoY), $35.3M in net income, and $31.3M in free cash flow against $156.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 41.1 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)
Even with a 78/100 (B+) score, CGEN faces multiple-compression risk if 5.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 84.8% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.32) or 200D SMA ($2.30) invalidates the momentum regime and cuts Target Base ($2.16) toward Bear Floor ($1.62).
Compugen Ltd. (CGEN) dropped -2.94% to $1.98, trading at 30% of its 52-week range ($1.43 – $3.24). High-quality cash engine (87% profit margin, 85% return on capital) with steady institutional support.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today announced that the Company will release its third quarter
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, r
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat a
Yahoo Finance coverage on CGEN stock catalysts, institutional flow, and earnings outlook.
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to e
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today reported financial results for the second quarter of 2
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second qua
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-pr
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +161.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CGEN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CGEN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Compugen Ltd. (CGEN) ranks #23 by composite RQD confidence (78/100, grade B+) and #581 by equity capitalization ($193.0M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CGEN
ACTIVE
Compugen Ltd. | B+ | 78/100 | 5.5x | 87.3% | 85.0% | -2.94% | $193.0M | Benchmark Subject |
| DTIL Precision BioSciences Inc. | E | 24/100 | — | — | -35.0% | -5.11% | $205.4M | /dtil-vs-cgen → |
| ARTV Artiva Biotherapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.95% | $206.8M | /artv-vs-cgen → |
| PALI Palisade Bio Inc. | D- | 43/100 | — | — | -35.0% | -2.52% | $207.4M | /pali-vs-cgen → |
| IVVD Invivyd Inc. | E | 30/100 | — | — | -35.0% | -3.37% | $177.4M | /ivvd-vs-cgen → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Compugen Ltd. (CGEN) reported GAAP revenue of $72.8M (+161.1% vs. FY2024 revenue of $27.9M , and +117.5% cumulative change since FY2023) , GAAP net income of $35.3M, operating cash flow of $31.6M, and free cash flow of $31.3M (-36.7% YoY). On the balance sheet, CGEN closed FY2025 with $156.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $72.8M | $35.3M | $31.6M | $31.3M | $156.6M | — |
| FY2024 (FY) | 2024-12-31 | $27.9M | -$14.2M | $49.6M | $49.5M | $115.0M | — |
| FY2023 (FY) | 2023-12-31 | $33.5M | -$18.8M | -$35.9M | -$35.9M | — | — |
As of 2026-11-02, Compugen Ltd. (NASDAQ: CGEN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1.98 (-2.94% 1D, market cap $193.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, CGEN ranks #23 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEN carries a Roarable B+ (78/100 RQD), trailing P/E of 5.5x, gross margin of 87.3%, and ROIC of 85.0%. By comparison, DTIL (Precision BioSciences Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M) and ARTV (Artiva Biotherapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per CGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001119774), Compugen Ltd. generated $72.8M in revenue (+161.1% YoY), $35.3M in net income, and $31.3M in free cash flow against $156.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
CGEN last traded at $1.98 (-2.94% on volume of 255,462 shares), positioning the stock -14.66% below its 50-day simple moving average ($2.32) and -13.91% below its 200-day simple moving average ($2.30). Across its 52-week range of $1.43 to $3.24, CGEN sits at the 30.4% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.76 to $2.20).
Why CGEN Stock dropped -2.94% Today — RQD Quant Desk Flash. High-quality cash engine (87% profit margin, 85% return on capital) with steady institutional support.
Per the Roarable RQD 5-pillar rating engine, Compugen Ltd. (CGEN) carries a composite score of 78/100 (B+ — Roarable Buy — Very Good Cash & Smart-Money Inflow) at a current price of $1.98 (-2.94%). Fundamental cash generation scores 14/20 (ROIC 85.0%, FCF yield 16.24%), institutional 13F whale accumulation scores 12/20, insider conviction scores 19/20, macro regime alignment scores 18/20 (Beta 1.00), and forensic balance-sheet protection scores 15/20 (Altman Z-Score N/A, Piotroski F-Score 7/9).
Investor Implication: At 5.5x trailing P/E and 4.6x forward P/E within Biotechnology: Biological Products (No Diagnostic Substances), upside depends on sustained operating margin expansion (43.1%) and free cash flow conversion relative to the 52-week range of $1.43 – $3.24.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), CGEN is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 87.3%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).
Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.
Real-time company headlines, analyst actions, and sector developments for Compugen Ltd. (CGEN) • Click "Debate This Headline" to argue it in the Roar Pit below
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today announced that the Company will release its third quarter
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, r
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat a
Yahoo Finance coverage on CGEN stock catalysts, institutional flow, and earnings outlook.
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to e
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today reported financial results for the second quarter of 2
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings
Welcome to the CGEN (Compugen Ltd.) Roar Pit. Current RQD Composite is 78/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CGEN, but look at what you are paying: 5.5x trailing P/E with 87.3% gross margins. Unless Compugen Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CGEN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.98 (52-wk range $1.43 - $3.24), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).